# Study of Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve Subjects

> **NCT01066962** · PHASE3 · COMPLETED · sponsor: **ANRS, Emerging Infectious Diseases** · enrollment: 800 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** darunavir/ritonavir QD + raltegravir BID
- **DRUG:** darunavir/r QD + tenofovir/emtricitabine QD (fixed dose combination)

## Key facts

- **NCT ID:** NCT01066962
- **Lead sponsor:** ANRS, Emerging Infectious Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2013-10
- **Final completion:** 2013-10
- **Target enrollment:** 800 (ACTUAL)
- **Last updated:** 2013-11-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01066962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01066962, "Study of Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01066962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*